Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Exagen (XGN) EBIAT (2018 - 2026)

Exagen filings provide 9 years of EBIAT readings, the most recent being -$4.0 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 5.73% to -$4.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$20.2 million, a 30.04% decrease, with the full-year FY2025 number at -$20.0 million, down 31.99% from a year prior.
  • EBIAT hit -$4.0 million in Q1 2026 for Exagen, up from -$4.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$3.0 million in Q2 2024 to a low of -$14.7 million in Q2 2022.
  • Median EBIAT over the past 5 years was -$5.0 million (2024), compared with a mean of -$6.5 million.
  • Biggest five-year swings in EBIAT: crashed 128.78% in 2022 and later surged 65.82% in 2023.
  • Exagen's EBIAT stood at -$14.4 million in 2022, then soared by 61.17% to -$5.6 million in 2023, then soared by 32.51% to -$3.8 million in 2024, then fell by 24.25% to -$4.7 million in 2025, then increased by 15.11% to -$4.0 million in 2026.
  • The last three reported values for EBIAT were -$4.0 million (Q1 2026), -$4.7 million (Q4 2025), and -$7.1 million (Q3 2025) per Business Quant data.